Logo
x

Search

Subscribe Now

hnscc

Moderna Report Results of mRNA-4157 + Keytruda in Interim P-l Study for HNSCC and MSS-CRC

Moderna Report Results of mRNA-4157 + Keytruda in Interim P-l Study for HNSCC and MSS-CRC

  • November 12, 2020
Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

    Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

    • May 14, 2024
    Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer

      Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer

      • April 10, 2024
      Aveo Entered into an Clinical Trial Collaboration and Supply Agreement with Eli Lilly to Evaluate Ficlatuzumab + Erbitux (cetuximab) for HNSCC in North America

        Aveo Entered into an Clinical Trial Collaboration and Supply Agreement with Eli Lilly to Evaluate Ficlatuzumab + Erbitux (cetuxima...

        • June 23, 2022
        AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to Evaluate Ficlatuzumab and Erbitux (cetuximab) for Recurrent or Metastatic HNSCC

          AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to Evaluate Ficlatuzumab and Erbitux (cetuximab) for Recurrent or...

          • January 5, 2022
          Moderna Report Results of mRNA-4157 + Keytruda in Interim P-l Study for HNSCC and MSS-CRC

            Moderna Report Results of mRNA-4157 + Keytruda in Interim P-l Study for HNSCC and MSS-CRC

            • November 12, 2020
            Image

            Incisive News in 3 Shots.

            Contact Us

            Our Information

            Follow Us

            Copyright © 2025 PharmaShots - All Rights Reserved.